Pink Oyster Mushroom

Metadata

Regulatory Status

United States

• FDA GRAS: Not specifically listed. However, Pleurotus species are broadly consumed as food.
• Dietary supplement: Available as a dietary supplement under DSHEA, primarily as dried powder or extract.
• Note: Not as widely marketed in the US as P. ostreatus; primarily available through specialty mushroom growers as a fresh culinary ingredient.

European Union

• Food status: Not specifically listed as a novel food; consumed in tropical regions with long culinary history. Regulatory status for supplement use unclear under EU Novel Food regulations.

Southeast Asia

• Status: Widely cultivated and consumed as a food across tropical Asia, particularly in Indonesia, Philippines, Thailand, and India. One of the most commonly cultivated oyster mushroom species in tropical climates due to its heat tolerance.

China

• Status: Cultivated and consumed as a food. Used as a general edible mushroom; not listed in the Chinese Pharmacopoeia.

Conditions & Indications

Primary Indications (Preclinical Evidence)

• Hyperlipidemia and cholesterol management — P. djamor contains naturally occurring lovastatin (~374 mcg/g dry weight), an HMG-CoA reductase inhibitor. While clinical trials on P. djamor specifically are absent, the lovastatin mechanism is identical to the FDA-approved pharmaceutical, and related Pleurotus species (P. ostreatus) have demonstrated cholesterol-lowering effects in human studies. The statin content, though lower than some P. ostreatus strains, supports potential cardiovascular benefit.
• Antioxidant protection — Ethanol extracts of P. djamor demonstrate antioxidant activity with an EC50 of 22.81 mcg/mL in DPPH scavenging assays, comparable to ascorbic acid (EC50 21.96 mcg/mL). Phenolic compounds including gallic acid and catechin contribute to free-radical scavenging capacity. Ergothioneine provides cellular antioxidant defense.

Secondary Indications (Preliminary Evidence)

• Antimicrobial activity — Extracts demonstrate inhibitory effects against Escherichia coli, Salmonella enterica serovar Typhi, and Salmonella enterica serovar Paratyphi in well-diffusion assays. Both wild and cultivated isolates show antibacterial properties.
• Antidiabetic potential — Hot water extract of P. djamor var. fuscopruinosus demonstrated alpha-glucosidase inhibition (IC50 = 582.91 mcg/mL), suggesting potential for blood glucose management. Mycelium zinc polysaccharides from P. djamor showed protective antioxidative effects in streptozocin-induced diabetic mice, reducing liver and kidney oxidative damage.
• Nutritional fortification — High protein content (18-33% dry weight depending on strain and substrate), rich in essential amino acids, dietary fiber (18-19%), B vitamins, and minerals. Serves as a protein-dense functional food in tropical regions.

Emerging/Preclinical Indications

• Anticancer activity — P. djamor var. fuscopruinosus extracts demonstrated anticancer effects in vitro. Pleurotus species lectins and polysaccharides broadly show anti-proliferative effects against cancer cell lines. Clinical translation is unestablished.
• Anti-inflammatory effects — Ergosterol derivatives including ergosterol peroxide demonstrate anti-inflammatory activity in preclinical models.

Mechanism of Action

Primary Mechanisms

1. Lovastatin inhibition of HMG-CoA reductase Lovastatin (mevinolin) is a naturally occurring prodrug hydrolyzed in vivo to its active beta-hydroxy acid form, which competitively inhibits 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase — the rate-limiting enzyme in the mevalonate pathway of cholesterol biosynthesis. P. djamor produces lovastatin at approximately 374 mcg/g dry weight. This is the same mechanism as the prescription drug lovastatin (Mevacor). The lovastatin exists in a food matrix that may modulate absorption kinetics compared to pharmaceutical formulations.

2. Polysaccharide-mediated immunomodulation Beta-1,3/1,6-D-glucans from P. djamor activate innate immune cells through pattern recognition receptors, primarily Dectin-1 and complement receptor 3 (CR3) on macrophages, natural killer cells, and neutrophils. This triggers downstream NF-kB and MAPK signaling, enhancing phagocytic activity, cytokine production, and immune surveillance.

3. Phenolic compound antioxidant activity Phenolic compounds including gallic acid, catechin, and flavonoids scavenge reactive oxygen species (ROS) through hydrogen atom transfer and single electron transfer mechanisms. The high total phenolic content contributes to DPPH radical scavenging, ABTS decolorization, and reducing power.

Secondary Mechanisms

4. Alpha-glucosidase inhibition Hot water extracts inhibit alpha-glucosidase enzyme activity, slowing carbohydrate digestion and postprandial glucose absorption in the gastrointestinal tract. This mechanism is shared with acarbose-type pharmaceutical agents.

5. Ergothioneine cytoprotection Ergothioneine, present in Pleurotus species, is a unique amino acid accumulated via the OCTN1 transporter in tissues under oxidative stress. It scavenges ROS, protects mitochondria, chelates metal ions, and modulates inflammatory signaling.

Key Active Compounds

Clinical Evidence Summary

Key Preclinical Studies

Evidence Limitations

• No human clinical trials have been conducted specifically on P. djamor for any endpoint. This is the single largest evidence gap.
• Most cardiovascular and cholesterol-lowering evidence is extrapolated from P. ostreatus studies, which may have different lovastatin concentrations and bioactive profiles.
• Lovastatin content varies significantly with cultivation substrate, strain, and growing conditions, complicating standardization.
• Antidiabetic and anticancer evidence is exclusively from in vitro and animal models; clinical translation is entirely unestablished.
• The pharmacokinetics of lovastatin delivered in P. djamor’s food matrix have not been characterized.
• Long-term safety data specific to P. djamor supplementation are absent.

Safety Profile

General Assessment

P. djamor has been consumed as an edible food across tropical Asia for centuries. As a culinary mushroom, its safety profile is well-established for dietary consumption. However, concentrated extracts may deliver pharmacologically relevant lovastatin doses, warranting caution similar to that advised for P. ostreatus extracts.

Contraindications

• Active liver disease: Statins are contraindicated in active liver disease. While dietary consumption is unlikely to deliver clinically significant lovastatin doses, concentrated extracts could approach pharmaceutical-relevant levels.
• Concurrent statin medication: Patients taking prescription statins should exercise caution with concentrated P. djamor extracts due to potential additive lovastatin exposure and increased myopathy risk.
• Pleurotus allergy: Oyster mushroom spores are recognized aeroallergens. Cross-reactivity among Pleurotus species is expected.
• Pregnancy and lactation: Statins are Category X in pregnancy. Culinary consumption at standard dietary amounts is likely safe, but concentrated lovastatin-containing extracts should be avoided.

Drug Interactions

• Prescription statin medications: Additive HMG-CoA reductase inhibition increases risk of myopathy and rhabdomyolysis. Severity: Moderate. Avoid concentrated extracts; culinary use is likely safe.
• CYP3A4 inhibitors (erythromycin, clarithromycin, itraconazole, ketoconazole, grapefruit juice): Lovastatin is metabolized by CYP3A4. Potent inhibitors increase lovastatin plasma levels. Severity: Moderate with concentrated extracts; low with dietary use.
• Fibrates (gemfibrozil, fenofibrate): Concomitant use with statins increases myopathy risk. Severity: Moderate.
• Immunosuppressants (cyclosporine): Increases lovastatin plasma levels. Severity: Moderate with concentrated extracts.
• Anticoagulants: Exercise standard caution. Severity: Low.

Side Effects

• From culinary consumption: No adverse effects reported at standard dietary intake. The fruiting body has a short shelf life and must be consumed fresh or dried promptly after harvest.
• From concentrated extracts: Potential for statin-related effects including myalgia, elevated creatine kinase, GI disturbance, and rarely elevated liver enzymes (dose-dependent).
• Allergic reactions: Spore-related hypersensitivity is possible, particularly in cultivation environments.

Toxicology

• No specific toxicological studies on P. djamor concentrated extracts have been published. Safety is inferred from the long history of culinary use and from the broader Pleurotus safety literature.

Clinical Dosage

Culinary Consumption

• Standard amount: 100-300 g fresh (10-30 g dried) per day as part of a regular diet
• Note: P. djamor has a delicate texture and mild, slightly sweet flavor. Cooking degrades some lovastatin content. Culinary consumption is unlikely to deliver pharmacologically significant statin doses.

Dried Fruiting Body Powder

• Estimated dose: 3-9 g/day of dried fruiting body powder (extrapolated from P. ostreatus studies)
• Lovastatin content: Approximately 374 mcg/g (0.037% dry weight), meaning a 5 g dose would deliver roughly 1.9 mg lovastatin equivalent — well below pharmaceutical doses (10-80 mg/day)
• Note: No standardized supplemental doses have been established specifically for P. djamor

Hot Water Extract

• Estimated dose: 1-3 g/day of hot water extract
• Primarily captures polysaccharides; lovastatin requires ethanol-based extraction

Important Note

All dosage recommendations are extrapolated from related Pleurotus species studies. No human clinical dosing data exist specifically for P. djamor. Consult a healthcare provider before supplementation, particularly if taking medications.

Sources

• Biochemistry Journal (2024). Estimation of lovastatin from Pleurotus species by thin layer chromatography. Archives, Vol. 8, Issue 2.
• Scientific Reports (2025). Identification and therapeutic efficacy of Pleurotus djamor var fuscopruinosus. Nature. doi:10.1038/s41598-025-02900-4
• Researchgate (2018). Antioxidant capacity and protein content of Pleurotus djamor cultivated on rice husk.
• Researchgate (2018). Bioactive compounds and medicinal properties of Oyster mushrooms (Pleurotus sp.).
• ScienceDirect (2022). Agro-industrial waste improves the nutritional and antioxidant profile of Pleurotus djamor.
• PubMed (2024). Nutritional and antioxidant potential of Pleurotus djamor produced on agronomic wastes banana leaves and sugarcane bagasse substrates. PMID: 38647869.
• PubMed (2016). The antioxidative effects of acidic-, alkalic-, and enzymatic-extractable mycelium zinc polysaccharides by Pleurotus djamor on liver and kidney of streptozocin-induced diabetic mice. PMID: 26683206.
• Agricultural Science Digest. Comparison of yield, nutrient content and antibacterial activities of wild and cultivated isolates of Pleurotus djamor.
• Korea Science (2020). Nutritional composition and antioxidant activity of pink oyster mushrooms (Pleurotus djamor var. roseus) grown on a paddy straw substrate.
• Springer (2020). Fruiting bodies of selected edible mushrooms as a potential source of lovastatin. Eur Food Res Technol.
• Taylor & Francis (2016). Therapeutic properties of Pleurotus species (oyster mushrooms) for atherosclerosis: A review. Int J Food Properties.

Connections

• Oyster Mushroom (P. ostreatus) — closest relative with extensively studied lovastatin content and cardiovascular clinical evidence; P. djamor evidence is largely extrapolated from P. ostreatus research
• King Oyster (P. eryngii) — another Pleurotus species with documented hypolipidemic effects in animal models
• Golden Oyster (P. citrinopileatus) — tropical Pleurotus species with similar cultivation characteristics and bioactive profile
• Shiitake — another lovastatin-containing culinary mushroom with cardiovascular applications
• Maitake — complementary cardiovascular and metabolic support mushroom used in combination protocols